{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:15:33Z","timestamp":1776849333527,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13300-026-01846-8","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:29:21Z","timestamp":1773131361000},"page":"571-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-Effectiveness of Highly Effective Glucose-Lowering Agents: Do Current Practices Optimize Clinical and Economic Outcomes?"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-1954-847X","authenticated-orcid":false,"given":"Meredith","family":"Hoog","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Minghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-6813","authenticated-orcid":false,"given":"William J.","family":"Valentine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"1846_CR1","unstructured":"World Health Organization. Diabetes. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/diabetes Accessed 11 Nov 2024."},{"key":"1846_CR2","unstructured":"American Diabetes Association. Annual report 2023. https:\/\/diabetes.org\/sites\/default\/files\/2024-06\/ADA_2023_AnnualReport.pdf Accessed 11 Nov 2024."},{"key":"1846_CR3","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics report. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html. Accessed 22 Nov 2024."},{"key":"1846_CR4","unstructured":"American Diabetes Association. Press Release. New American Diabetes Association report finds annual costs of diabetes to be $412.9 billion. https:\/\/diabetes.org\/newsroom\/press-releases\/new-american-diabetes-association-report-finds-annual-costs-diabetes-be. Accessed 11 Nov 2024."},{"issue":"1","key":"1846_CR5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1846_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"CX Ma","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21(1):74.","journal-title":"Cardiovasc Diabetol"},{"key":"1846_CR7","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45(Suppl 1):S125\u2013143.","DOI":"10.2337\/dc22-S009"},{"key":"1846_CR8","unstructured":"National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Health and economic benefits of diabetes interventions. https:\/\/www.cdc.gov\/nccdphp\/priorities\/diabetes-interventions.html. Accessed 11 Nov 2024."},{"issue":"11","key":"1846_CR9","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.2337\/dc13-0331","volume":"36","author":"K Khunti","year":"2013","unstructured":"Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411\u20137.","journal-title":"Diabetes Care"},{"issue":"12","key":"1846_CR10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13098-020-00559-7","volume":"17","author":"F Andreozzi","year":"2020","unstructured":"Andreozzi F, Candido R, Corrao S, Fornengo R, Giancaterini A, Ponzani P, et al. Clinical inertia is the enemy of therapeutic success in the management of diabetes and its complications: a narrative literature review. Diabetol Metab Syndr. 2020;17(12):52.","journal-title":"Diabetol Metab Syndr"},{"key":"1846_CR11","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","DOI":"10.2337\/dci22-0034"},{"key":"1846_CR12","unstructured":"American Diabetes Association Professional Practice Committee; 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Supplement_1):S181\u2013206."},{"issue":"35","key":"1846_CR13","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehaa082","volume":"41","author":"F Marsico","year":"2020","unstructured":"Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell\u2019Aversana S, Esposito I, et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2020;41(35):3346\u201358.","journal-title":"Eur Heart J"},{"issue":"2","key":"1846_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148\u201358.","journal-title":"JAMA Cardiol"},{"key":"1846_CR15","unstructured":"Eli Lilly and Company. Press release. FDA approves Lilly\u2019s Mounjaro injection. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and#:~:text=INDIANAPOLIS%20%2C%20May%2013%2C%202022%20%2F,as%20an%20adjunct%20to%20diet. Accessed 25 Nov 2024."},{"key":"1846_CR16","doi-asserted-by":"crossref","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al.; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","DOI":"10.1016\/S0140-6736(21)02188-7"},{"issue":"1","key":"1846_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s40200-024-01553-w","volume":"24","author":"P Arietti","year":"2025","unstructured":"Arietti P, Boye KS, Guidi M, Rachman J, Federici MO, Raiola R, et al. Improving outcomes with early and intensive metabolic control in patients with type 2 diabetes: a long-term modeling analysis of clinical and cost outcomes in Italy. J Diabetes Metab Disord. 2025;24(1):58.","journal-title":"J Diabetes Metab Disord"},{"issue":"1","key":"1846_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4158\/CS-2018-0535","volume":"25","author":"AJ Garber","year":"2019","unstructured":"Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142019 executive summary. Endocr Pract. 2019;25(1):69\u2013100.","journal-title":"Endocr Pract"},{"issue":"8","key":"1846_CR19","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","volume":"65","author":"T Karagiannis","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, et al. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022;65(8):1251\u201361.","journal-title":"Diabetologia"},{"issue":"5","key":"1846_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/ijcp.12361","volume":"68","author":"S Brunton","year":"2014","unstructured":"Brunton S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other? Int J Clin Pract. 2014;68(5):557\u201367.","journal-title":"Int J Clin Pract"},{"key":"1846_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076410","volume":"384","author":"H Yao","year":"2024","unstructured":"Yao H, Zhang A, Li D, Wu Y, Wang CZ, Wan JY, et al. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis. BMJ. 2024;384:e076410.","journal-title":"BMJ"},{"issue":"3","key":"1846_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061807","volume":"13","author":"H Ma","year":"2023","unstructured":"Ma H, Lin YH, Dai LZ, Lin CS, Huang Y, Liu SY. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight\/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2023;13(3):e061807.","journal-title":"BMJ Open"},{"issue":"1","key":"1846_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/13696998.2022.2035132","volume":"25","author":"RF Pollock","year":"2022","unstructured":"Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ. 2022;25(1):393\u2013402.","journal-title":"J Med Econ"},{"issue":"10","key":"1846_CR24","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2013","unstructured":"Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2013;316(10):1093\u2013103.","journal-title":"JAMA"},{"issue":"3","key":"1846_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/dc20-2304","volume":"44","author":"M Fang","year":"2021","unstructured":"Fang M, Selvin E. Thirty-year trends in complications in U.S. adults with newly diagnosed type 2 diabetes. Diabetes Care. 2021;44(3):699\u2013706.","journal-title":"Diabetes Care"},{"key":"1846_CR26","doi-asserted-by":"crossref","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","DOI":"10.1056\/NEJMoa2107519"},{"key":"1846_CR27","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (update). NICE Guideline. https:\/\/www.nice.org.uk\/guidance\/ng28\/evidence\/health-economic-model-report-pdf-10959500845. Accessed 11 Nov 2024."},{"key":"1846_CR28","doi-asserted-by":"crossref","unstructured":"Gnesin F, Thuesen ACB, K\u00e4hler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020;6(6):CD012906.","DOI":"10.1002\/14651858.CD012906.pub2"},{"issue":"10","key":"1846_CR29","first-page":"519","volume":"63","author":"I Romera","year":"2016","unstructured":"Romera I, Ampudia-Blasco FJ, P\u00e9rez A, Ari\u00f1o B, Pfarr E, Giljanovic Kis S, et al. Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus. Endocrinolog\u00eda y Nutrici\u00f3n (Engl Edn). 2016;63(10):519\u201326.","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n (Engl Edn)"},{"issue":"2","key":"1846_CR30","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/dom.14234","volume":"23","author":"SE Inzucchi","year":"2021","unstructured":"Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I, et al. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):425\u201333.","journal-title":"Diabetes Obes Metab"},{"key":"1846_CR31","doi-asserted-by":"crossref","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al.; LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39\u201347.","DOI":"10.1016\/S0140-6736(09)60659-0"},{"issue":"3","key":"1846_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.2337\/dc20-1473","volume":"44","author":"JP Frias","year":"2021","unstructured":"Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. Efficacy and safety of dulaglutide 3.0\u00a0mg and 4.5\u00a0mg versus dulaglutide 1.5\u00a0mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes Care. 2021;44(3):765\u201373.","journal-title":"Diabetes Care"},{"issue":"3","key":"1846_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jval.2016.10.004","volume":"20","author":"M Willis","year":"2017","unstructured":"Willis M, Asseburg C, Nilsson A, Johnsson K, Kartman B. Multivariate prediction equations for HbA1c lowering, weight change, and hypoglycemic events associated with insulin rescue medication in type 2 diabetes mellitus: informing economic modeling. Value Health. 2017;20(3):357\u201371.","journal-title":"Value Health"},{"issue":"10","key":"1846_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14656","volume":"38","author":"J Leal","year":"2021","unstructured":"Leal J, Alva M, Gregory V, Hayes A, Mihaylova B, Gray AM, et al. Estimating risk factor progression equations for the UKPDS outcomes model 2 (UKPDS 90). Diabet Med. 2021;38(10):e14656.","journal-title":"Diabet Med"},{"issue":"3","key":"1846_CR35","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2215\/CJN.07650711","volume":"7","author":"G Zoppini","year":"2012","unstructured":"Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7(3):401\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl. 1","key":"1846_CR36","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.2337\/dc22-S006","volume":"45","author":"American Diabetes Association","year":"2022","unstructured":"American Diabetes Association. Standard of medical care in diabetes\u20142022. Diabetes Care. 2022;45(suppl. 1):S83\u201396.","journal-title":"Diabetes Care"},{"issue":"12","key":"1846_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107735","volume":"34","author":"W Yang","year":"2020","unstructured":"Yang W, Cintina I, Hoerger T, Neuwahl SJ, Shao H, Laxy M, et al. Estimating costs of diabetes complications in people <65\u00a0years in the U.S. using panel data. J Diabetes Complications. 2020;34(12):107735.","journal-title":"J Diabetes Complications"},{"issue":"2","key":"1846_CR38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40258-014-0086-9","volume":"12","author":"J Yeaw","year":"2014","unstructured":"Yeaw J, Halinan S, Hines D, Delozier A, Perez M, Boye M, et al. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy. 2014;12(2):219\u201330.","journal-title":"Appl Health Econ Health Policy"},{"key":"1846_CR39","unstructured":"Bureau of Labor Statistics Website. Consumer price index for all urban consumers: medical care in US city average, all urban consumers, not seasonally adjusted. https:\/\/beta.bls.gov\/dataViewer\/view\/timeseries\/CUUR0000SAM. Accessed 11 Nov 2024."},{"issue":"7","key":"1846_CR40","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40273-019-00775-8","volume":"37","author":"H Shao","year":"2019","unstructured":"Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: the health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37(7):921\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1846_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","volume":"21","author":"MA Nauck","year":"2022","unstructured":"Nauck MA, D\u2019Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.","journal-title":"Cardiovasc Diabetol"},{"issue":"14","key":"1846_CR42","doi-asserted-by":"publisher","first-page":"1161521","DOI":"10.3389\/fendo.2023.1161521","volume":"21","author":"R Ruze","year":"2023","unstructured":"Ruze R, Liu T, Zou X, Song J, Chen Y, Xu R, et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol (Lausanne). 2023;21(14):1161521.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1846_CR43","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00125-021-05539-8","volume":"64","author":"R Folz","year":"2021","unstructured":"Folz R, Laiteerapong N. The legacy effect in diabetes: are there long-term benefits? Diabetologia. 2021;64(10):2131\u20137.","journal-title":"Diabetologia"},{"issue":"3","key":"1846_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (The Diabetes & Aging Study). Diabetes Care. 2019;42(3):416\u201326.","journal-title":"Diabetes Care"},{"issue":"3","key":"1846_CR45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.12997\/jla.2023.12.3.213","volume":"12","author":"YK Cho","year":"2023","unstructured":"Cho YK, La Lee Y, Jung CH. The cardiovascular effect of tirzepatide: a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide dual agonist. J Lipid Atheroscler. 2023;12(3):213\u201322.","journal-title":"J Lipid Atheroscler"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01846-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01846-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:17:32Z","timestamp":1776845852000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01846-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1846"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01846-8","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Meredith Hoog is an employee of Eli Lilly and Company. Alice Minghetti and William J. Valentine are employees of Ossian Health Economics and Communications, which has received financial support from Eli Lilly and Company for consulting services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}